.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,105,626

« Back to Dashboard

Claims for Patent: 8,105,626

Title:Granules containing acid-unstable chemical in large amount
Abstract: It is intended to provide preparations such as capsules containing an acid-unstable medicament (in particular, a benzimidazole compound having an antiulcer effect, etc.) at a high concentration which are prepared by using about 12% by weight or more (based on the total granules) of the acid-unstable chemical and blending a basic inorganic salt therewith to give granules of about 600 .mu.m or more in the average particle size.
Inventor(s): Shimizu; Toshihiro (Itami, JP), Nakano; Yoshinori (Takarazuka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:10/492,690
Patent Claims: 1. A capsule comprising lansoprazole-containing granules, wherein said granules comprise: a principal ingredient layer comprising lansoprazole or an optically active isomer thereof or a pharmaceutically acceptable salt thereof in an amount of 12% by weight or more based on the total granules, and one or more basic inorganic salts in an amount of 0.2 part by weight to 0.4 part by weight based on 1 part by weight of lansoprazole or the optically active isomer thereof or the pharmaceutically acceptable salt thereof; an intermediate coating layer which is formed on the principal ingredient layer; an enteric coating layer which is formed on the intermediate coating layer; and a core; wherein: the principal ingredient layer is formed on the core, the amount of the intermediate coating layer to be coated is 0.02 part by weight to 1.5 parts by weight on 1 part by weight of the granules containing lansoprazole or the optically active isomer thereof or the pharmaceutically acceptable salt thereof, the amount of the enteric coating layer to be coated is 10% by weight to 70% by weight based on the total amount of the granules before coating of the enteric coating, and the average particle size of the granules is 600 .mu.m to about 2500 .mu.m.

2. The capsule according to claim 1, wherein the one or more basic inorganic salts are selected from the group consisting of basic salts of a sodium salt, a potassium salt, an aluminum salt, a magnesium salt and a calcium salt.

3. The capsule according to claim 2, wherein the one or more basic inorganic salts are selected from the group consisting of a magnesium salt and a calcium salt.

4. The capsule according to claim 1, wherein the amount of the intermediate coating layer to be coated is 0.05 part by weight to 1 part by weight on 1 part by weight of the granules containing lansoprazole or the optically active isomer thereof or the pharmaceutically acceptable salt thereof.

5. The capsule according to claim 1, wherein the amount of the enteric coating layer to be coated is 10% by weight to 50% by weight based on the total amount of the granules before coating of the enteric coating.

6. The capsule according to claim 1, wherein the core comprises at least one material selected from the group consisting of sucrose, starch, lactose and crystalline cellulose.

7. The capsule according to claim 1, wherein the enteric coating layer comprises an enteric water-soluble polymer.

8. The capsule according to claim 7, wherein the enteric water-soluble polymer is a methacrylic acid copolymer.

9. The capsule according to claim 1, wherein an average particle size of the granules is 1000 .mu.m to 2000 .mu.m.

10. The capsule according to claim 1, comprising lansoprazole or the optically active isomer thereof or the pharmaceutically acceptable salt thereof in an amount of 12% by weight to 40% by weight based on the total granules.

11. The capsule according to claim 1, which is a capsule for treating or preventing peptic ulcer, Zollinger-Ellison syndromes, gastritis, reflux esophagitis, symptomatic gastroesophageal reflux disease (symptomatic GERD), NUD (non ulcer dyspepsia), stomach cancer, gastric MALT lymphoma, ulcer resulting from nonsteroidal antiinflammatory medicaments, or excess stomach acid or ulcer due to post-operation stress, a preparation for eradicating Helicobacter pylori, or a preparation for suppressing upper gastrointestinal hemorrhage due to peptic ulcer, acute stress ulcer, hemorrhagic gastritis or invasion stress.

12. The capsule according to claim 3, wherein the basic inorganic salt is magnesium carbonate.

13. The capsule according to claim 1, which is a No. 3 to 5 capsule comprising 30 mg of lansoprazole.

14. The capsule according to claim 1, which is a No. 4 to 5 capsule comprising 15 mg of lansoprazole.

15. The capsule according to claim 1, which is a No. 1 to 3 capsule comprising 60 mg of lansoprazole or an optically active isomer (R isomer) thereof.

16. The capsule according to claim 1, which is a No. 2 to 4 capsule comprising 40 mg of an optically active isomer (R isomer) of lansoprazole.

17. The capsule according to claim 1, which is a No. 3 to 5 capsule comprising 30 mg of an optically active isomer (R isomer) of lansoprazole.

18. A pharmaceutical composition which is a combination of an antimicrobial agent and the capsule according to claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc